

## BIOGRAPHICAL SKETCH

NAME <b>Marks, Leonard S.</b>	POSITION TITLE <b>Medical Director, Urological Sciences Research Foundation Clinical Professor of Urology, UCLA</b>		
CONTACT INFORMATION <b>3831 Hughes Avenue Suite 701, Culver City CA, 90232 Phone: 310-559-9800 Email: lsmarks@usrf.org</b>			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Tulane University, New Orleans, LA	BA	1965	Psychology
University of Texas, Galveston TX	MD	1969	Medicine
University of Texas, Galveston TX	MA	1969	Physiology

### A. Post-Doctoral Education

- 1969-1970 Intern in Surgery, UCLA/Harbor General Hospital; Torrance, California
- 1972-1973 Resident in Surgery, UCLA/Harbor General Hospital; Torrance, California
- 1973-1974 Post-Doctoral Research, Department of Surgery, University of California, Los Angeles, California
- 1973-1974 Renal Hypertension Research Fellow, Cedars-Sinai Medical Center; Los Angeles, California
- 1974-1978 Resident in Urology, University of California, Los Angeles, California

### B. Positions and Honors

- 1965 Bachelor of Arts with Honors, Tulane University, New Orleans, Louisiana
- 1969 Alpha Omega Alpha
- 1976 Clinical Research Prize, Grayson Carroll, Essay Contest, Americal Urological Association: "Angiotensin Blockade in Renovascular Hypertension: A Controlled, Prospective Study"
- 1976 Resident's Research Prize, Los Angeles Urological Society: "Angiotensin Blockade in the Rapid Detection of Renovascular Hypertension"
- 1993 – 1995 American Foundation for Urologic Disease Research Awards - "Normalization of Serum PSA levels in Men with Benign Prostatic Hyperplasia: Role of Prostatic Epithelial Quantification"
- 2000-2001 CapCURE Research Award - "Biomarker Expression in Benign and Malignant Prostate Tissues of Native Japanese and Japanese- American Men"
- 2000 – present Associate Member, Early Detection Research Network, Division of Cancer Prevention, National Cancer Institute. "Free PSA Molecular Forms (BPSA & proPSA): BIOMARKER ROLE." In collaboration with the Brady Urological Institute of Johns Hopkins University.

### C. Experience and Employment

- Texas State Licensure, 1969
- California State Licensure, 1972
- Diplomate, American Board of Urology, Year of Election 1980
- Clinical Professor, Department of Urology, University of California, Los Angeles, CA
- Hospital Staff Appointment, University of California, California
  - Saint John's Hospital, Santa Monica, California
  - Daniel Freeman Hospital, Inglewood, California
- Founding Director, Urological Sciences Research Foundation, A California Non-profit Corporation, Los Angeles, California
- Advisory Council, Brotman Medical Center, Culver City, California
- Prostate Cancer Advisory Board, Merck & Company, Atlanta Georgia
- 1991-present Editorial Review Board, Urology (The Gold Journal)

1998-present Associate Editor, Urology (The Gold Journal)  
1996-present Website Director, Urological Sciences Research Foundation, <http://www.usrf.org>

**D. Selected peer-reviewed publications (in chronological order)**

- Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse HG, Groskopf J: Prostate cancer specificity of PCA3 Urinary Gene Test. *Urology* 69: 532-535, 2007.
- Marks LS, Mazer N, Hess D, Dorey F, Epstein J, Veltri R, Makarov D, Partin A, Bostwick D, Macairan M, Mostaghel E, Nelson P. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial. *JAMA* 2006;296:2351-61
- Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. *J Urol.* 2006 Oct;176(4 Pt 1):1299-306
- Marks LS, Hess DL, Dorey FJ, Macairan ML. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. *J. Urol.*, 2006 Aug;68(2):337-41.
- Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. Interpretation of Serum Prostate Specific Antigen Levels in Men Receiving 5 alpha-Reductase Inhibitors: A Review and Clinical Recommendations. *J. Urol.* 2006 Sep;176(3):868-74. Review.
- Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS. Relationship among Serum Testosterone, Sexual Function, and Response to Treatment in Men Receiving Dutasteride for Benign Prostatic Hyperplasia. *J. Clin. Endocrinol. Metab.* 2006 Apr;91(4):1323-8.
- Groskopf J, Aubin SM, Deras, IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. Aptima PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer. *Clin Chem.* 2006 Jun;52(6):1089-95.
- Baker S, Brawley O, Marks LS. Untreated Syphilis in Negro Male: A Closure Comes to the Tuskegee Study. *Urology* 65: 1259, 2005.
- Marks LS, Kojima M, DeMarzo A, et al. Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue, *Urology* 2004 Oct; 64 (4) 765-711
- Roehrborn CG, Marks LS, Fenter TC, et al. Efficacy and safety of dutasteride in the four-year treatment of prostatic hyperplasia. Accepted for publication, *Urology* (April, 2004 issue).
- Marks LS. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1- year implant. *Urology* 2003 Dec 22;62 (6 Suppl 1):36-42.
- Partin AW, Roehrborn CG, Lieber MM, and Marks LS. PSA as a biomarker for benign prostatic hyperplasia disease progression. *Advanced Studies in Medicine of Johns Hopkins University* 3 (4D): S347-61, 2003.
- Marks LS, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. *Urology* 2003 Nov;62(5):888-93.
- Marks LS. Treatment of men with minimally symptomatic benign prostatic hyperplasia--PRO: the argument in favor. *Urology* 2003 Nov;62(5):781-3.
- Marks LS. Editorial comment on Efficacy of tadalafil for treatment of erectile dysfunction at 24 and 36 hours after dosing. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varnese L, and Rosen R. *Urology* 62:121, 2003.
- Veltri RW, Marks LS, Miller MC, Bales WD, Fan J, Macairan ML, Epstein JI, Partin AW. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. *Urology.* 2002 Oct;60(4):617.
- Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders Jr. FE, Pantuck AJ and Tyler VE. PC-SPEs: herbal formulation for prostate cancer. *Urology* 60: 369-377, 2002.
- Harry J. Linton, Leonard S. Marks, Lisa S. Millar, Christine L. Knott, Harry G. Rittenhouse, Stephen D. Mikolajczyk Benign prostate-specific antigen (BPSA) a subform of free prostate specific antigen in serum, is elevated in men with benign prostate disease. *Clinical Chemistry.* 2003 Feb;49(2):253-9.
- Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. *Urology.* 2002 Jun;59(6):797-802.
- Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto

- and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. *Urology* 57: 999-1005, 2001.
- Marks LS, Epstein JI, Partin, AW. The role of prostate needle biopsy in evaluation of chemopreventive agents. *Urology* 57: 191-3, 2001.
- Partin AW and Marks LS. Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents. *Urology* 57: 132-6, 2001.
- Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. *J Urol.* 163: 1451-56, 2000.
- Simon I, Snow PB, Marks LS, Christens-Barry WA, Epstein JI, Bluemke DA, Partin AW. Neural network prediction of prostate tissue composition based on MRI analysis. *Anal Quant Cytol Histol.* 22: 445-52, 2000.
- Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS, and Slawin KM. Seminal plasma contains "BPSA," a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia. *Prostate* 45: 271-6, 2000.
- Marks LS. The fundamental concept, that interindividual differences among prostate glands can explain varying responses to treatment, remains intact. A simple test to pinpoint those differences remains the challenge. *Urology* 56: 266, 2000.
- Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, and Slawin KM. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. *Cancer Research* 60: 756-9, 2000.
- Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM, Slawin KM. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. *Urology* 55: 41-5, 2000.
- Marks LS, Ettekal B, Cohen MS, Macairan ML, Vidal J. Use of a shapememory alloy (nitinol) in a removable prostate stent. *Tech Urol.* 5: 226-30, 1999.
- Mikolajczyk SD, Millar LS, Marker KM, Rittenhouse HG, Wolfert RL, Marks LS, Charlesworth MC, Tindall DJ. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. *Cancer Res.* 59: 3927-30, 1999.
- Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Long-term effects of finasteride on prostate tissue composition. *Urology* 53: 574-80, 1999.
- Marks LS and Tyler VE. Saw palmetto extract: Newest (and oldest) treatment for men with Symptomatic Benign Prostatic Hyperplasia. *Urology* 53: 457-61, 1999.
- Marks LS, Duda C, Dorey FJ, Macairan ML, and Santos PB. Treatment of erectile dysfunction with sildenafil (Viagra). *Urology* 53: 19-24, 1999 (1<sup>st</sup> article in this journal to be electronically posted with full text and graphics: <http://www-east.elsevier.com/url/>).
- Epstein JI, Partin AW, Shue M, Shery ED, Marks LS. Histological changes in benign prostate biopsies following long-term, finasteride therapy for benign prostatic hyperplasia. *J Urol Path* 10: 87-95, 1999.
- Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong ENP, Kelley CA, Stoner E, and Partin AW. Influence of Finasteride on Free and Total Serum Prostate Specific Antigen Levels in Men with Benign Prostatic Hyperplasia. *J Urol.* 159: 449-53, 1998.
- Marks LS, Dorey FJ, Macairan ML, Park C, and deKernion JB. 3-D Ultrasound Device for Rapid Determination of Bladder Volume. *Urology* 50: 341-8, 1997.
- Marks LS, Partin AW, Gormley GJ, Dorey FJ, Shery ED, Garris J, deKernion JB, and Stoner E. Prostate Tissue Composition and Response to Finasteride vs. Placebo in Men with Symptomatic BPH. *J Urol.* 157:2171-8, 1997.
- Marks LS, Penson D, Maller J, Nielsen RT, and deKernion JB. Computergenerated graphical presentations: Use of multimedia to enhance communication. *Urology* 49: 2-9, 1997.
- Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse HG, Partin AW, and deKernion JB. Serum PSA levels after TURP: Longitudinal characterization in men with BPH. *J of Urol.* 156: 1035-9, 1996.
- Williams RD, Gleason DM, Smith AY, et al. Pilot Study of intravesical alpha-2b interferon for treatment of bladder carcinoma in situ following BCG failure. *J of Urol.* 155: 494 (A), 1996.